Thrombosis & Haemostasis Research Review, Issue 23

In this issue:

Enoxaparin vs aspirin thromboprophylaxis after joint replacement
Bridging thrombolysis before thrombectomy improves stroke outcomes
Bridging therapy remains the standard treatment for stroke
Rivaroxaban protects against VTE in patients with PAD
OVID finds no benefit to anticoagulation in outpatients with COVID-19
ETHIC: enoxaparin not efficacious for non-critical outpatients with COVID-19
ABO O blood group is a risk factor for platelet reactivity in HIT
Efmoroctocog alfa safe and efficacious for severe paediatric haemophilia A
INR haemorrhage risk data from warfarin users cannot be extrapolated to CLD
Apixaban non-inferior to dalteparin for VTE regardless of cancer location
Aberrant sleep duration and napping in older adults increases risk of CVD
 

Please login below to download this issue (PDF)

Subscribe